TRPA1 ankyrin repeat six interacts with a small molecule inhibitor chemotype

Area of Science:

• Pharmacology
• Molecular Biology
• Neuroscience

Background:

• Transient receptor potential ankyrin 1 (TRPA1) channel is implicated in pain signaling.
• Existing TRPA1 inhibitors face challenges with lipophilicity, solubility, and pharmacokinetics.
• Novel interaction sites are needed for developing improved TRPA1-targeting analgesics.

Purpose of the Study:

• To identify novel small molecule inhibitors of the TRPA1 channel.
• To characterize the interaction site of a new class of TRPA1 inhibitors.
• To explore new therapeutic strategies for pain management.

Main Methods:

• Screening for novel TRPA1 inhibitors.
• Utilizing species ortholog chimeric and mutagenesis strategies to identify interaction sites.
• Employing computational modeling to predict key amino acid residues.
• Validating predicted residues through mutagenesis experiments.

Main Results:

• A novel thiadiazole structural class of TRPA1 inhibitors was identified.
• The interaction site was localized to ankyrin repeat 6 (ANK6) in the N-terminal region of TRPA1.
• Three critical amino acids (G238, N249, K270) in human TRPA1 were confirmed to be essential for compound activity.

Conclusions:

• A previously undescribed small molecule interaction site on TRPA1 has been established.
• This discovery opens new avenues for developing TRPA1 inhibitor analgesics with potentially improved properties.
• The findings contribute to understanding TRPA1 channel gating mechanisms.